Back to GetFilings.com



Table of Contents

 
 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q

     
þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the quarterly period ended March 31, 2005

OR

     
o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    Commission File Number 0-11250

DIONEX CORPORATION

 
(Exact name of registrant as specified in its charter)
     
Delaware   94-2647429
     
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)
     
1228 Titan Way, Sunnyvale, California   94085
     
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (408) 737-0700

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YES R NO £

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

YES R NO £

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of May 6, 2005:

     
CLASS   NUMBER OF SHARES
     
Common Stock   20,291,859
 
 

 


DIONEX CORPORATION
INDEX

             
        Page  
 
  PART I. FINANCIAL INFORMATION        
 
           
  FINANCIAL STATEMENTS        
 
           
 
  CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2005 and June 30, 2004     3  
 
           
 
  CONDENSED CONSOLIDATED STATEMENTS OF INCOME Three Months Ended March 31,
2005 and 2004
    4  
 
           
 
  CONDENSED CONSOLIDATED STATEMENTS OF INCOME Nine Months Ended March 31, 2005
and 2004
    5  
 
           
 
  CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Nine Months Ended March 31,
2005 and 2004
    6  
 
           
 
  NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS     7-12  
 
           
  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS     13-21  
 
           
  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS     21-22  
 
           
  CONTROLS AND PROCEDURES     22  
 
           
 
  PART II. OTHER INFORMATION        
 
           
  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS     23  
 
           
  EXHIBITS     24-25  
 
           
        26  
 
           
        27  
 EXHIBIT 10.15
 EXHIBIT 31.1
 EXHIBIT 31.2
 EXHIBIT 32.1
 EXHIBIT 32.2

2.


Table of Contents

DIONEX CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
(Unaudited)

                 
    March 31,     June 30,  
    2005     2004  
ASSETS
               
Current assets:
               
Cash and cash equivalents
  $ 42,927     $ 46,673  
Short-term investments
    24,454       12,113  
Accounts receivable (net of allowance for doubtful accounts of $907 at March 31, 2005 and $760 at June 30, 2004)
    56,883       53,128  
Inventories
    27,220       24,838  
Deferred taxes
    10,659       10,293  
Prepaid expenses and other
    4,056       3,875  
 
           
Total current assets
    166,199       150,920  
Property, plant and equipment, net
    49,311       46,656  
Goodwill
    25,126       24,675  
Intangible assets, net
    3,333       4,357  
Other assets
    8,194       8,857  
 
           
 
  $ 252,163     $ 235,465  
 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Notes payable to banks
  $ 140     $ 1,468  
Accounts payable
    8,417       8,113  
Accrued liabilities
    30,897       31,822  
Income taxes payable
    95       2,214  
Accrued product warranty
    3,820       3,584  
 
           
Total current liabilities
    43,369       47,201  
Deferred taxes
    3,615       3,557  
Other long-term liabilities
    869       1,253  
Stockholders’ equity:
               
Preferred stock (par value $.001 per share; 1,000,000 shares authorized; none outstanding)
             
Common stock (par value $.001 per share; 80,000,000 shares authorized; issued and outstanding:
               
20,706,957 shares at March 31, 2005 and 20,840,881 shares at June 30, 2004)
    122,495       103,943  
Retained earnings
    69,040       71,217  
Accumulated other comprehensive income
    12,775       8,294  
 
           
Total stockholders’ equity
    204,310       183,454  
 
           
 
  $ 252,163     $ 235,465  
 
           

See notes to condensed consolidated financial statements.

3.


Table of Contents

DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
THREE MONTHS ENDED MARCH 31, 2005 AND 2004
(In thousands, except per share amounts)
(Unaudited)

                 
    Three Months Ended  
    March 31,  
    2005     2004  
Net sales
  $ 70,801     $ 70,746  
Cost of sales
    22,941       24,629  
 
           
Gross profit
    47,860       46,117  
 
           
Operating expenses:
               
Selling, general and administrative
    26,060       23,367  
Research and product development
    4,801       4,606  
 
           
Total operating expenses
    30,861       27,973  
 
           
Operating income
    16,999       18,144  
Interest income
    351       214  
Interest expense
    (4 )     (66 )
Other income (expense), net
    67       60  
 
           
Income before taxes
    17,413       18,352  
Taxes on income
    5,453       5,965  
 
           
Net income
  $ 11,960     $ 12,387  
 
           
Basic earnings per share
  $ 0.58     $ 0.58  
 
           
Diluted earnings per share
  $ 0.56     $ 0.56  
 
           
Shares used in computing per share amounts:
               
Basic
    20,763       21,180  
 
           
Diluted
    21,543       22,177  
 
           

See notes to condensed consolidated financial statements.

4.


Table of Contents

DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
NINE MONTHS ENDED MARCH 31, 2005 AND 2004
(In thousands, except per share amounts)
(Unaudited)

                 
    Nine Months Ended  
    March 31,  
    2005     2004  
Net sales
  $ 208,161     $ 189,561  
Cost of sales
    69,190       64,474  
 
           
Gross profit
    138,971       125,087  
 
           
Operating expenses:
               
Selling, general and administrative
    73,895       65,429  
Research and product development
    15,127       14,204  
 
           
Total operating expenses
    89,022       79,633  
 
           
Operating income
    49,949       45,454  
Interest income
    890       530  
Interest expense
    (136 )     (170 )
Other income (expense), net
    380       (268 )
 
           
Income before taxes
    51,083       45,546  
Taxes on income
    16,732       14,803  
 
           
Net income
  $ 34,351     $ 30,743  
 
           
Basic earnings per share
  $ 1.66     $ 1.46  
 
           
Diluted earnings per share
  $ 1.59     $ 1.40  
 
           
Shares used in computing per share amounts:
               
Basic
    20,755       21,099  
 
           
Diluted
    21,561       21,983  
 
           

See notes to condensed consolidated financial statements.

5.


Table of Contents

DIONEX CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
NINE MONTHS ENDED MARCH 31, 2005 AND 2004
(In thousands)
(Unaudited)

                 
    Nine Months Ended  
    March 31,  
    2005     2004  
Cash flows from operating activities:
               
Net income
  $ 34,351     $ 30,743  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Depreciation and amortization
    4,528       4,372  
Gain on sale of marketable securities
    (644 )      
Tax benefit related to stock option plans
    5,177       6,313  
Deferred taxes
    (120 )     (937 )
Changes in assets and liabilities:
               
Accounts receivable
    (1,788 )     (6,202 )
Inventories
    (1,074 )     1,216  
Prepaid expenses and other assets
    (1,045 )     (344 )
Accounts payable
    122       4,818  
Accrued liabilities
    1,450       121  
Income taxes payable
    (2,500 )     (4,417 )
Accrued product warranty
    107       248  
 
           
Net cash provided by operating activities
    38,564       35,931  
 
           
Cash flows from investing activities:
               
Earnout provision of LC Packings
    (3,500 )     (3,000 )
Purchase of marketable securities
    (50,475 )     (16,550 )
Proceeds from sale of marketable securities
    39,522       4,451  
Purchase of property, plant and equipment
    (5,175 )     (3,108 )
Acquisition of other intangible assets
          (975 )
Proceeds from sale of property & equipment
    4        
Other
    64       91  
 
           
Net cash used for investing activities
    (19,650 )     (19,091 )
 
           
Cash flows from financing activities:
               
Net change in revolving line of credit
    (942 )     662  
Principal payments on debt
    (423 )     (484 )
Proceeds from issuance of common stock
    17,365       17,794  
Repurchase of common stock
    (40,520 )     (30,458 )
 
           
Net cash used for financing activities
    (24,520 )     (12,486 )
 
           
Effect of exchange rate changes on cash
    1,770       1,195  
 
           
Net increase in cash and equivalents
    (3,746 )     5,549  
Cash and equivalents, beginning of period
    46,673       40,821  
 
           
Cash and equivalents, end of period
  $ 42,927     $ 46,370  
 
           
Supplemental disclosures of cash flow information:
               
Income taxes paid
  $ 13,470     $ 13,371  
Interest paid
  $ 93     $ 126  

See notes to condensed consolidated financial statements.

6.


Table of Contents

DIONEX CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation

     The condensed consolidated financial statements included herein have been prepared by Dionex Corporation (the “Company”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. It is suggested that these condensed consolidated financial statements be read in conjunction with the condensed consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2004.

     The unaudited condensed consolidated financial statements included herein reflect all adjustments (which include only normal, recurring adjustments) that are, in the opinion of management, necessary to state fairly the results for the periods presented. The results for such periods are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2005.

2. Reclassification of Auction Rate Securities (“ARS”)

     The Company has determined that investments in auction rate securities should be classified as short-term investments. Previously, such investments had been classified as cash and cash equivalents. ARS generally have long-term maturities; however, these investments have characteristics similar to short-term investments because at predetermined intervals, generally every 28 to 49 days, there is a new auction process, and a ready market exists for these securities. The Company recorded investments in ARS as of March 31, 2005 as short-term investments and reclassified ARS as of June 30, 2004 that were previously included in cash and cash equivalents as short-term investments.

     The following is a summary of the effects of the reclassification (in thousands):

                         
    Consolidated Balance Sheet  
                   
    As Previously              
As of June 30, 2004   Reported     Adjustments     As Reclassified  
Cash and cash equivalents
  $ 57,182     $ (10,509 )   $ 46,673  
Short-term investments
    1,604       10,509       12,113  

3. Stock-Based Compensation

     The Company applies Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees” (APB No. 25) and related interpretations in accounting for its stock-based compensation plans. Accordingly, no accounting recognition is given to stock options granted at fair market value until they are exercised. Upon exercise, net proceeds, including tax benefits realized, are credited to equity.

7.


Table of Contents

     Statement of Financial Accounting Standards (SFAS) No. 123, “Accounting for Stock-Based Compensation,” sets forth a fair-value based method of recognizing stock-based compensation expense. As permitted by SFAS No. 123, the Company has elected to continue to apply APB No. 25 to account for its stock-based compensation plans. Had compensation costs under the Company’s stock-based compensation plans been determined based on the fair value at the grant dates consistent with the method set forth under SFAS No. 123, the effect on the Company’s net income and earnings per share would have been as follows (in thousands, except per share amounts):

                                 
    Three Months Ended     Nine Months Ended  
    March 31,     March 31,  
    2005     2004     2005     2004  
Net income, as reported
  $ 11,960     $ 12,387     $ 34,351     $ 30,743  
Less: Total stock-based employee compensation expense determined under fair value method for all awards, net of related tax effects
    1,265       1,283       4,340       4,066  
 
                       
Pro forma net income
  $ 10,695     $ 11,104     $ 30,011     $ 26,677  
 
                       
Earnings per share:
                               
Basic — as reported
  $ 0.58     $ 0.58     $ 1.66     $ 1.46  
 
                       
Basic — pro forma
  $ 0.52     $ 0.52     $ 1.45     $ 1.26  
 
                       
Diluted — as reported
  $ 0.56     $ 0.56     $ 1.59     $ 1.40  
 
                       
Diluted — pro forma
  $ 0.50     $ 0.50     $ 1.39     $ 1.21  
 
                       

     The resulting pro forma compensation expense may not be representative of the amount to be expected for the year ending June 30, 2005. Pro forma compensation expense may be greater as additional options are granted.

     The fair value of each option on the date of grant is estimated using the Black-Scholes option-pricing model with a volatility of 47% for 2005 and 49% for 2004, expected life of options of 5.6 years for 2005 and 5.9 years for 2004, risk free interest rate of approximately 3.56% in 2005 and 3.30% in 2004 and a dividend yield of 0% for fiscal years 2005 and 2004, respectively.

     The Black-Scholes option-pricing model was developed for estimating the fair value of publicly traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including expected stock price volatility. The Company’s employee stock options have characteristics significantly different from publicly traded options, and changes in the subjective input assumptions can materially affect the fair value estimate.

4. New Accounting Pronouncements

     In September 2004, the Financial Accounting Standards Board (FASB) issued FASB Staff Position (FSP) Emerging Issues Task Force (EITF) Issue 03-1, Effective Date of Paragraphs 10-20 of EITF Issue No. 03-1, “The Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investments”, which delays the effective date for the recognition and measurement guidance in EITF Issue No. 03-1. In addition, the FASB has issued a proposed FSP to consider whether further application guidance is necessary for securities analyzed for impairment under EITF Issue No. 03-1. The Company continues to assess the potential impact of the adoption of the proposed FSP could have on the Company’s consolidated financial statements.

     In November 2004, the FASB issued SFAS No. 151, “Inventory Costs” (SFAS No. 151) which clarifies the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material. SFAS No. 151 will be effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The Company continues to assess the potential impact the adoption of SFAS No. 151 could have on the Company’s consolidated financial statements.

     In December 2004, the FASB issued SFAS No. 123R, “Share-Based Payment” (SFAS 123R), which eliminates the alternative of applying the intrinsic value measurement to stock compensation awards issued to employees. Rather, the new standard requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award. That cost will be recognized over the period during which an employee is required to provide services in exchange for the award, as is referred to as the requisite service period (usually the vesting period).

8.


Table of Contents

     The Company has not yet quantified the effects of the adoption of SFAS 123R, but it is expected that the new standard will result in significant stock-based compensation expense. The pro forma effects on net income and earnings per share if the Company had applied the fair value recognition provisions of original SFAS 123 on stock compensation awards are disclosed in Note 3. Although such pro forma effects of applying original SFAS 123 may be indicative of the effects of adopting SFAS 123R, the provisions of these two statements differ in some important respects. The actual effect of adopting SFAS 123R will be dependent on numerous factors including, but not limited to, the valuation model chosen by the Company to value stock-based awards; the assumed award forfeiture rate; the accounting policies adopted concerning the method of recognizing the fair value of awards over the requisite service period; and the transition method (as described below) chosen for adopting SFAS 123R.

     SFAS 123R will be effective for the Company’s fiscal quarter beginning July 1, 2005, and requires the use of the Modified Prospective Application Method. Under this method SFAS 123R will be applied to new awards and to awards modified, repurchased or cancelled after the effective date. Additionally, compensation cost for the portion of awards for which the requisite service has not been rendered (such as unvested options) that are outstanding as of the date of adoption shall be recognized as the remaining requisite services are rendered. The compensation cost relating to unvested awards at the date of adoption shall be based on the grant-date fair value of those awards as calculated for pro forma disclosures under the original SFAS 123. In addition, companies may use the Modified Retrospective Application Method. This method may be applied to all prior years for which the original SFAS 123 was effective or only to prior interim periods in the year of initial adoption. If the Modified Retrospective Application Method is applied, financial statements for prior periods shall be adjusted to give effect to the fair-value-based method of accounting for awards on a consistent basis with the pro forma disclosures required for those periods under the original SFAS 123.

     In December 2004, the FASB issued SFAS No. 153, “Exchanges of Nonmonetary Assets, an amendment of APB Opinion No. 29” (SFAS No. 153) which eliminates the exception for nonmonetary exchanges of similar productive assets and replaces it with a general exception for exchanges of nonmonetary assets that do not have commercial substance. SFAS No. 153 will be effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. The Company expects that the adoption of SFAS No. 153 will not have any impact on the Company’s condensed consolidated financial statements.

5. Marketable Securities

     During the year ended June 30, 2004, the Company acquired debt instruments with maturities of more than one year. These securities are classified as “held-to-maturity” securities. At March 31, 2005, the aggregate unamortized value of these securities was approximately $4.2 million, of which approximately $1.0 and $3.2 million are classified on the balance sheet as “short-term investments” and “other assets”, respectively. The aggregate amount of unrealized losses for these securities was approximately $97,000 at March 31, 2005, all of which had been in a loss position for less than 12 months. In the three months ended March 31, 2005 the Company sold a “held to maturity” security. The Company realized proceeds of $97,000 and reported a loss of $2,600 on the sale.

6. Inventories

     Inventories consist of (in thousands):

                 
    March 31,     June 30,  
    2005     2004  
Finished goods
  $ 14,850     $ 13,208  
Work in process
    2,110       2,654  
Raw materials
    10,260       8,976  
 
           
 
  $ 27,220     $ 24,838  
 
           

9.


Table of Contents

7. Comprehensive Income

     Comprehensive income is the change in stockholders’ equity arising from transactions other than investments by owners and distributions to owners. For the Company, the significant components of comprehensive income, other than net income, are foreign currency translation adjustments and net unrealized gains or losses on securities available for sale. The components of accumulated other comprehensive income is summarized as follows (in thousands):

                                 
    Three Months Ended     Nine Months Ended  
    March 31,     March 31,  
    2005     2004     2005     2004  
Net income, as reported
  $ 11,960     $ 12,387     $ 34,351     $ 30,743  
Foreign currency translation adjustments
    (4,147 )     (938 )     4,731       6,351  
Unrealized gain/(loss) on securities available for sale, net
    (32 )     (7 )     (249 )     157  
 
                       
Comprehensive income
  $ 7,781     $ 11,442     $ 38,833     $ 37,251  
 
                       

8. Common Stock Repurchases

     During the three months ended March 31, 2005, the Company repurchased 246,300 shares of its common stock on the open market for approximately $14.3 million (at an average repurchase price of $58.19 per share), compared with 316,700 shares repurchased for approximately $16.9 million (at an average repurchase price of $53.31 per share) in the same period in the prior fiscal year.

     During the nine months ended March 31, 2005, the Company repurchased 767,500 shares of its common stock on the open market for approximately $40.5 million (at an average repurchase price of $52.80 per share) compared with 652,700 shares repurchased for approximately $30.5 million (at an average repurchase price of $46.66 per share) in the same period in the prior year.

     During the year ended June 30, 2004, the Company repurchased a total of 1,116,300 shares of its common stock on the open market for approximately $53.7 million (at an average repurchase price of $48.11 per share).

9. Earnings Per Share

     Basic earnings per share is determined by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is determined by dividing net income by the weighted average number of common shares used in the basic earnings per share calculation, plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding under the treasury stock method.

     The following table is a reconciliation of the numerators and denominators used in computing basic and diluted earnings per share (in thousands, except per share data):

                                 
    Three Months Ended     Nine Months Ended  
    March 31,     March 31,  
    2005     2004     2005     2004  
Numerator:
                               
Net Income
  $ 11,960     $ 12,387     $ 34,351     $ 30,743  
Denominator:
                               
Weighted average shares used to compute net income per common share
— basic
    20,763       21,180       20,755       21,099  
Effect of dilutive stock options
    780       997       806       884  
 
                       
Weighted average shares used to compute net income per common share
— diluted
    21,543       22,177       21,561       21,983  
 
                       
Basic earnings per share
  $ 0.58     $ 0.58     $ 1.66     $ 1.46  
 
                       
Diluted earnings per share
  $ 0.56     $ 0.56     $ 1.59     $ 1.40  
 
                       

     Antidilutive common equivalent shares related to stock options are excluded from the calculation of diluted shares. At March 31, 2005 and 2004 all stock options were included in the diluted earnings per share calculation.

10.


Table of Contents

10. Goodwill and Other Intangible Assets

     Information regarding the Company’s goodwill and other intangible assets reflects current foreign exchange rates.

     Changes in the carrying amount of goodwill for the nine months ended March 31, 2005 are as follows (in thousands):

         
    Total  
Balance as of July 1, 2004
  $ 24,675  
Goodwill acquired during the period
     
Translation adjustments
    451  
 
     
Balance as of March 31, 2005
  $ 25,126  
 
     

     The Company performed an annual impairment test of goodwill in April 2005 and determined that goodwill was not impaired.

     Information regarding the Company’s other intangible assets follows (in thousands):

                                                 
    As of March 31, 2005     As of June 30, 2004  
    Carrying     Accumulated             Carrying     Accumulated        
    Amount     Amortization     Net     Amount     Amortization     Net  
Developed technology
    10,057       (7,864 )     2,193       9,750       (6,505 )     3,245  
Other
    1,341       (201 )     1,140       1,186       (74 )     1,112  
 
                                   
Total
  $ 11,398     $ (8,065 )   $ 3,333     $ 10,936     $ (6,579 )   $ 4,357  
 
                                   

     The Company amortizes developed technology over a period of three to seven years and the remaining weighted average amortization period for this category approximates two years. The Company amortizes other intangibles over a period of five to ten years and the remaining weighted average amortization period for this category approximates eight years.

     Amortization expense related to intangible assets was $354,000 and $1.2 million, respectively, for the three and nine months ended March 31, 2005 as compared to $396,000 and $1.1 million, respectively, for the three and nine months ended March 31, 2004. The estimated amortization for each of the five fiscal years subsequent to June 30, 2004 is as follows:

         
Year Ending   Amortization  
    June 30,   Expense  
2005
  $ 1,600  
2006
    1,068  
2007
    870  
2008
    364  
2009
    155  
Thereafter
    445  
 
     
Total
  $ 4,502  
 
     

11. Warranty

     Product warranties are recorded at the time revenue is recognized for certain product shipments. Warranty expense is affected by product failure rates, material usage and service costs incurred in correcting a product failure. Should actual product failure rates, material usage or service costs differ from our estimates, revisions to the warranty liability would be required.

11.


Table of Contents

     Details of the change in accrued product warranty for the nine months ended March 31, 2005 and 2004 are as follows (in thousands):

                                         
    Balance   Provision           Actual   Balance
    Beginning   for           Warranty   End of
    of Period   Warranties(2)   Other(1)   Costs Incurred(3)   Period
Accrued Product Warranty
Nine Months Ended:
                                       
 
                                       
March 31, 2005
  $3,584       1,705       134       (1,603 )   $3,820  
                                       
 
                                       
March, 31, 2004
  $3,188       1,797       172       (1,563 )   $3,594  
                                       


(1) Effects of exchange rate changes
(2) Provision for warranties related to products sold during the period
(3) Costs of warranty claims processed during the period

12. Commitments

     One of the Company’s foreign subsidiaries discounts trade notes receivable with banks. The uncollected balances of notes receivable due to the discounting banks at March 31, 2005 and June 30, 2004 were $2.7 million and $7.4 million, respectively. The Company is contingently liable for these unpaid balances to the extent the amounts are not paid to the bank by the end customer. The Company has determined that the carrying amount of its contingent liability under this guarantee was insignificant at March 31, 2005 and June 30, 2004 based on its past experience of discounting trade notes receivable.

12.


Table of Contents

DIONEX CORPORATION

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statement Regarding Forward-Looking Statements

     Except for historical information contained herein, the discussion below and in the footnotes to the Company’s financial statements contained in this Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, and are made under the safe harbor provisions thereof. Such statements are subject to certain risks, uncertainties and other factors that may cause actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements, or industry results, expressed or implied by such forward-looking statements. Such risks and uncertainties include, among other things: general economic conditions, foreign currency fluctuations, fluctuations in worldwide demand for analytical instrumentation, fluctuations in quarterly operating results, competition from other products, existing product obsolescence, new product development, including market receptiveness, the ability to manufacture products on an efficient and timely basis and at a reasonable cost and in sufficient volume, the ability to attract and retain talented employees and other risks as described in more detail below under the heading “Risks and Uncertainties.” Readers are cautioned not to place undue reliance on these forward-looking statements that reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to update these forward-looking statements.

The Company

     Dionex Corporation (the “Company”) is a leading manufacturer and marketer of chromatography systems for chemical analysis. The Company’s systems are used in environmental analysis and by the pharmaceutical, life sciences, chemical, petrochemical, power generation, food and electronic industries in a variety of applications.

Results of Operations — Three Months Ended March 31, 2005 and 2004

     Net sales for the third quarter of fiscal 2005 were $70.8 million, compared with $70.7 million reported for the same period in the prior year. The Company is subject to the effects of foreign currency fluctuations that have an impact on net sales and gross profit. Overall, currency fluctuations increased reported net sales by approximately 2% for the three months ended March 31, 2005 compared to 11% for the same period in the prior year.

     In the third quarter of fiscal 2005, net sales increased or decreased compared to the third quarter of fiscal 2004 as indicated in the table below:

         
    Three Months  
    Ended  
    March 31, 2004  
    to  
Percentage change in net sales   March 31, 2005  
Total:
    0 %
By geographic region:
       
North America
    -1 %
Europe
    5 %
Asia/Pacific
    -6 %
 
       
Percentage of change in net sales excluding currency fluctuations
       
 
       
Total:
    -2 %
By geographic region:
       
North America
    -2 %
Europe
    0 %
Asia/Pacific
    -7 %

13.


Table of Contents

     Net sales for the third quarter of fiscal 2005 in North America decreased from the third quarter of fiscal 2004 primarily due to weaker conditions in the environmental and pharmaceutical markets due to reduced customer and governmental spending. Net sales for the third quarter of fiscal 2005 in Europe increased from the third quarter of fiscal 2004 primarily due to good sales growth in the United Kingdom and France. The Asia/Pacific region declined primarily due to $5 million of nonrecurring sales in Japan related to new drinking water regulations reported in the third quarter last year. Excluding this incremental revenue in the prior period, Asia/Pacific region net sales increased 23% for the third quarter fiscal 2005, as we saw continued strong growth in all countries outside of Japan.

     Gross margin for the third quarter ended March 31, 2005 was 67.6% compared to 65.2% in the third quarter last year. Gross margin improved significantly from the third quarter last year. In the third quarter last year, the incremental $5 million in sales from Japan, described above, included an OEM component that had a significantly lower gross margin, causing our gross margin to be approximately 2 percentage points lower.

     Operating expenses of $30.9 million for the third quarter of fiscal 2005 increased $2.9 million, or 10.3%, from the $28.0 million reported in the same quarter last year. As a percentage of net sales described above, operating expenses increased to 43.6% for the three months ended March 31, 2005 compared to 39.5% for the same quarter last year.

     Selling, general and administrative (SG&A) expenses increased $2.7 million or 11.5%, to $26.1 million in the three months ended March 31, 2005 compared to $23.4 million for the same quarter last year. As a percentage of net sales, SG&A expenses increased to 36.8% for the third quarter of fiscal 2005 compared to 33.0% for the same quarter last year. The increase in SG&A expenses was primarily due to higher personnel costs of approximately $600,000, effects from currency fluctuations of approximately $800,000 and the costs of the Company’s Australian subsidiary (established in May 2004) and compliance with Section 404 of the Sarbanes-Oxley Act of approximately $300,000 each.

     Research and product development (R&D) costs of $4.8 million for the three months ended March 31, 2005 increased $195,000, or 4.2%, from the $4.6 million reported in the same period last year. Increased R&D spending in the three months ending March 31, 2005 is primarily due to higher personnel costs. Overall, the level of R&D spending varies depending on both the breadth of the Company’s R&D efforts and the stage of specific product development. In the third quarter of fiscal 2005, the Company introduced two new high end systems, the ICS-3000 Premiere Ion Chromatography system and the Ultimate 3000 Micro, Capillary and Nano flow system.

     Other income was $67,000 in the three months ended March 31, 2005 compared to income of $60,000 for the same period in the prior year. Other income in fiscal 2005 is attributable to foreign currency exchange gains.

     The effective tax rate for the three months ended March 31, 2005 was 31.3%, down from 32.5% reflected in the same period last year. The lower tax rate was due to tax credits that were recognized in the current quarter.

     Net income in the three months ended March 31, 2005 declined 3.4% to $12.0 million compared with $12.4 million reported for the same period last year. Diluted earnings per share for the three months ended March 31, 2005 were $.56, unchanged from the $.56 reported for the same period last year.

Results of Operations — Nine Months Ended March 31, 2005 and 2004

     Net sales for the nine months ended March 31, 2005 were $208.2 million, an increase of 10% over the $189.6 million reported for the same period last year. The Company is subject to the effects of foreign currency fluctuations that have an impact on net sales and gross profit. Overall, currency fluctuations increased net sales by approximately 4% for the first nine months of fiscal 2005 and by approximately 8% for the same period last year.

14.


Table of Contents

     Net sales for the first nine months of fiscal 2005 increased over the same period last year as indicated in the table below:

         
    Nine Months Ended  
Percentage change in net sales   March 31, 2004 to  
    March 31, 2005  
Total:
    10 %
By geographic region:
       
North America
    7 %
Europe
    12 %
Asia/Pacific
    10 %
 
       
Percentage of growth in net sales excluding currency fluctuations
       
Total:
    6 %
By geographic region:
       
North America
    6 %
Europe
    4 %
Asia/Pacific
    8 %

     Net sales in North America increased primarily due to improvements in economic conditions. Net sales in Europe increased primarily due to strong growth throughout the region. Net sales in the Asia/Pacific region increased primarily due to strong growth in all countries except Japan, resulting from the incremental sales previously discussed. The sales growth in the first nine months of fiscal 2005 was affected by the weaker third quarter sales growth. The Company believes that the fourth quarter will continue to be affected by weaker economic conditions and $3.0 million in nonrecurring sales in Japan in the fourth quarter of fiscal 2004.

     Gross margin for the first nine months of fiscal 2005 was 66.8%, a slight increase from the 66.0% reported for the same period last year. Gross margin was higher due to the high OEM component previously discussed in the third quarter last year.

     Operating expenses of $89.0 million for the first nine months of fiscal 2005 increased $9.4 million, or 11.8%, from the $79.6 million reported for the same period last year. As a percentage of sales, operating expenses in the first nine months of fiscal year 2005 were 42.8%, compared with 42.0% in the same period last year.

     SG&A expenses were $73.9 million for the first nine months of fiscal 2005, an increase of 12.9% compared with the $65.4 million reported in the same period last year. The increase in SG&A expenses was due to personnel costs of approximately $3.0 million, effects of currency fluctuations of approximately $2.8 million, costs associated with Sarbanes-Oxley Section 404 compliance activities of approximately $1.7 million, and the Company’s expansion efforts internationally in Korea and Australia of approximately $1.1 million.

     R&D costs for the first nine months of fiscal 2005 were $15.1 million, an increase of 6.5% compared with the $14.2 million reported in the same period last year. R&D costs in fiscal 2005 increased due to the Company’s higher spending for project materials and personnel costs to develop the Company’s IC and HPLC products. The level of R&D spending varies depending on both the breadth of the Company’s R&D efforts and the stage of specific product development.

     Other income was $380,000 for the first nine months of fiscal 2005 primarily due to a gain on the sale of marketable equity securities of $644,000 partially offset by losses on foreign exchange. Other expense was $268,000 for the first nine months of fiscal 2004, resulting from losses incurred in the Company’s foreign currency hedging activities.

     The effective tax rate for the first nine months of fiscal 2005 was 32.8%, up from 32.5% for the same period last year. The increase was attributable to a higher portion of foreign-sourced income in the current fiscal year. The Company’s tax rate is subject to fluctuation due to changes in tax regulations in the jurisdictions in which the Company does business.

     Net income for the first nine months of fiscal 2005 was $34.4 million, an increase of 11.7% compared with $30.7 million reported for the same period last year. Diluted earnings per share for the first nine months of fiscal 2005 were $1.59, an increase of 13.6% over the $1.40 reported for the same period last year.

15.


Table of Contents

Liquidity and Capital Resources

     At March 31, 2005, the Company had cash and cash equivalents of $42.9 million. The Company’s working capital was $122.8 million, an increase of $19.1 million from the $103.7 million reported at June 30, 2004. Cash generated by operating activities for the nine months ended March 31, 2005 was $38.6 million compared with $35.9 million for the same period last year. The increase in operating cash flow was primarily due to increases in net income, higher collections of accounts receivable and lower income tax payments partially offset by higher payments to suppliers and higher inventory levels related to higher sales and new products.

     Cash used for investing activities was $19.6 million and $19.1 million in the nine months ended March 31, 2005 and 2004, respectively. For nine months of fiscal 2005, investments included the purchases of marketable securities, net of proceeds from sales, for $11.0 million, capital expenditures of $5.2 million and the payment of $3.5 million for LC Packings earn-out. Capital expenditures for the first nine months of fiscal 2005 include costs to implement several information technology and business-related strategic initiatives. For the nine months of fiscal 2004, investments included purchases of marketable securities, net of proceeds from sales, for $12.1 million, capital expenditures of $3.1 million, payment of LC Packings earn-out of $3.0 million and $975,000 of intangibles related to our Korean subsidiary. Capital expenditures in fiscal 2004 included building improvements at the corporate headquarters and computer hardware and software spending in connection with the Company’s website.

     Cash used for financing activities was $24.5 million and $12.5 million in the first nine months of fiscal 2005 and 2004, respectively. The increase is primarily attributable to the repurchase of 767,500 shares of the Company’s common stock for $40.5 million in fiscal 2005 (at an average repurchase price of $52.80 per share) compared with 652,700 shares for $30.5 million in fiscal 2004 (at an average repurchase price of $46.66 per share), partially offset by proceeds received from the issuance of common stock for the exercise of employee stock options and from the employee stock purchase plan of $17.4 million in fiscal 2005 and $17.8 million in fiscal 2004.

     At March 31, 2005, the Company had utilized $140,000 of its $34.9 million in committed bank lines of credit, due to borrowings related to the Company’s Japanese operations. The Company believes that its cash flow from operations, current cash and cash investments and the remainder of its bank lines of credit will be adequate to meet its cash requirements for fiscal 2005 and the foreseeable future, and at least the next twelve months.

     The following table summarizes the Company’s contractual obligations at June 30, 2004, and the effect such obligations are expected to have on its liquidity and cash flows in future periods (in thousands):

                                         
    Payments Due by Period  
            Less                    
            Than 1     1-3     4-5     After 5  
Contractual Obligations   Total     Year     Years     Years     Years  
Lines of Credit
  $ 917     $ 917     $     $     $  
Mortgage Note Payable
    551       551                    
Operating Lease Obligations
    15,307       3,752       4,655       2,521       4,379  
Other Obligations
    3,500       3,500                    
 
                             
Total Contractual Commitments
  $ 20,275     $ 8,720     $ 4,655     $ 2,521     $ 4,379  
 
                             

     At June 30, 2004, the Company had recorded $3.5 million of Other Obligations in its condensed consolidated financial statements. Other Obligations relate to the earn-out from the acquisition of LC Packings in fiscal 2000 and recorded within “Accrued liabilities.” This earn-out payment in “Other Obligations” was made in January 2005.

     There have been no material changes to the Company’s contractual obligations outside ordinary business activities since June 30, 2004, except those changes described above related to earn-out payments and outstanding borrowings.

New Accounting Pronouncements

     In September 2004, the Financial Accounting Standards Board (FASB) issued FASB Staff Position (FSP) Emerging Issues Task Force (EITF) Issue 03-1, Effective Date of Paragraphs 10-20 of EITF Issue No. 03-1, “The Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investments”, which delays the effective date for the recognition and measurement guidance in EITF Issue No. 03-1. In addition, the FASB has issued a proposed FSP to consider whether further application guidance is necessary for securities analyzed for impairment under EITF Issue No. 03-1. The Company continues to assess the potential impact the adoption of the proposed FSP could have on the Company’s consolidated financial statements.

16.


Table of Contents

     In November 2004, the FASB issued Statement of Financial Accounting Standards (SFAS) No. 151, “Inventory Costs “ (SFAS No. 151) which clarifies the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material. SFAS No. 151 will be effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The Company continues to assess the potential impact the adoption of SFAS No. 151 could have on the Company’s consolidated financial statements.

     In December 2004, the FASB issued SFAS No. 123R, “Share-Based Payment” (SFAS 123R), which eliminates the alternative of applying the intrinsic value measurement to stock compensation awards issued to employees. Rather, the new standard requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of the award. That cost will be recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

     The Company has not yet quantified the effects of the adoption of SFAS 123R, but it is expected that the new standard may result in significant stock-based compensation expense. The pro forma effects on net income and earnings per share if the Company had applied the fair value recognition provisions of original SFAS 123 on stock compensation awards are disclosed in Note 3. Although such pro forma effects of applying original SFAS 123 may be indicative of the effects of adopting SFAS 123R, the provisions of these two statements differ in some important respects. The actual effect of adopting SFAS 123R will be dependent on numerous factors including, but not limited to, the valuation model chosen by the Company to value stock-based awards; the assumed award forfeiture rate; the accounting policies adopted concerning the method of recognizing the fair value of awards over the requisite service period; and the transition method (as described below) chosen for adopting SFAS 123R.

     SFAS 123R will be effective for the Company’s fiscal quarter beginning July 1, 2005, and requires the use of the Modified Prospective Application Method. Under this method SFAS 123R applied to new awards and to awards modified, repurchased, or cancelled after the effective date. Additionally, compensation cost for the portion of awards for which the requisite service has not been rendered (such as unvested options) that are outstanding as of the date of adoption shall be recognized as the remaining requisite services are rendered. The compensation cost relating to unvested awards at the date of adoption shall be based on the grant-date fair value of those awards as calculated for pro forma disclosures under the original SFAS 123. In addition, companies may use the Modified Retrospective Application Method. This method may be applied to all prior years for which the original SFAS 123 was effective or only to prior interim periods in the year of initial adoption. If the Modified Retrospective Application Method is applied, financial statements for prior periods shall be adjusted to give effect to the fair-value-based method of accounting for awards on a consistent basis with the pro forma disclosures required for those periods under the original SFAS 123.

     In December 2004, the FASB issued SFAS No. 153, “Exchanges of Nonmonetary Assets, an amendment of APB Opinion No. 29” (SFAS 153) which eliminates the exception for nonmonetary exchanges of similar productive assets and replaces it with a general exception for exchanges of nonmonetary assets that do not have commercial substance. SFAS 153 will be effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. The Company expects that the adoption of SFAS 153 will not have any impact on the Company’s consolidated financial statements.

Critical Accounting Policies and Estimates

Summary:

     The preparation of consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company evaluates its estimates on an on-going basis, including those related to product returns and allowances, bad debts, inventory valuation, goodwill and intangible assets, income taxes, warranty provisions, and contingencies.

     The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.

17.


Table of Contents

Revenue Recognition Policy

The Company derives revenues from the sale of products, the delivery of services to its customers, including installation and training, and from maintenance, which includes product repair obligations under extended warranty, unspecified software upgrades, telephone support and time and material repairs. Generally, the Company’s products contain embedded software that is essential to their functionality.

The Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104 “Revenue Recognition” and Statement of Position 97-2, “Software Revenue Recognition,” as amended, when persuasive evidence of an arrangement exists, the product has been delivered, or service performed, the price is fixed or determinable, collection is probable and vendor specific objective evidence exists to allocate revenue to the various elements of the arrangement. In all cases, the portion of revenue allocated to the undelivered elements is deferred until those items are delivered to the customer or the services are performed. Delivery of the product is generally considered to have occurred when shipped. Undelivered elements in the Company’s sales arrangements, which are not considered to be essential to the functionality of a product, generally include product accessories, installation services and/or training that are delivered after the related products have been delivered. Installation consists of system set-up, calibration and basic functionality training and generally requires one to three days depending on the product. Vendor specific objective evidence for product, product accessories and training services is based on the price charged when an element is sold separately or, if not sold separately, when the price is established by authorized management. The fair value of installation services is calculated by applying standard service billing rates to the estimate of the number of hours to install a specific product based on historical experience. These estimated hours for installation have historically been accurate and consistent from product to product. However, to the extent these estimates were to reflect unfavorable variability, the Company’s ability to maintain vendor specific objective evidence of fair value for such element could be impacted which in turn could delay the recognition of the revenue currently allocated to the delivered elements.

The Company recognizes revenue under extended warranty arrangements (maintenance fees) ratably over the period of the related maintenance contract and cost of the time and material repairs when incurred. Maintenance consists of product repair obligations under extended warranty, unspecified software upgrades, telephone support and time and material repairs. The Company’s equipment typically includes a one-year warranty. The estimated cost of product warranty claims is accrued at the time the sale is recognized, based on historical experience. While the Company believes its historical experience provides a reliable basis for estimating such warranty cost, unforeseen quality issues or component failure rates could result in future costs in excess of such estimates, or alternatively, improved quality and reliability in its products could result in actual expenses that are below those currently estimated.

The Company’s sales are typically not subject to rights of return and, historically, actual sales returns have not been significant.

Loss Provisions on Accounts Receivable and Inventory

     The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The Company assesses collectibility based on a number of factors including, but not limited to, past transaction history with the customer, the credit worthiness of the customer, independent credit reports, industry trends and the macro economic environment. Sales returns and allowances are estimates of future product returns related to current period revenue. Material differences may result in the amount and timing of the Company’s revenue for any period. Historically, the Company has not experienced significant bad debt losses.

     The Company values all of its inventories at the lower of standard cost (which approximates cost on a first-in, first-out basis) or market. The Company estimates revisions to its inventory valuations based on technical obsolescence, historical demand, projections of future demand, and industry and market conditions. If actual future demand or market conditions are less favorable than those projected by management, additional valuation provisions may be required. If demand or market conditions are more favorable, then higher margins could be realized to the extent inventory is sold which had previously been written down.

18.


Table of Contents

Long-Lived Assets, Intangible Assets with Finite Lives and Goodwill

     The Company assesses the impairment of long-lived assets, intangible assets with finite lives and goodwill whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In addition, the Company assesses goodwill for impairment at least annually. Factors the Company considers important that could trigger an impairment review include but are not limited to the following:

  •   significant underperformance relative to historical or projected future operating results;
 
  •   significant negative industry or economic trends; and
 
  •   significant changes or developments in strategic technology.

     When the Company determines that the carrying value of long-lived assets, intangible assets with finite lives may not be recoverable based upon the existence of one or more of the above or other indicators, it measures any impairment based on a projected discounted cash flow method using a discount rate determined by the Company’s management to be commensurate with the risk inherent in the Company’s current business model. Goodwill is tested for impairment by comparing the fair values of related reporting units to their carrying values. The Company completed its annual review in April, 2004 and at that time found that no impairment was necessary.

Income Taxes

     As part of the process of preparing the condensed consolidated financial statements, the Company is required to estimate its income taxes in each of the jurisdictions in which it operates. This process involves the Company’s estimate of its actual current tax exposure together with assessing temporary differences resulting from differing treatment of items, such as depreciation, amortization, and inventory reserves, for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the Company’s condensed consolidated balance sheets.

     The Company must then assess the likelihood that its deferred tax assets will be recovered from future taxable income and to the extent the Company believes that recovery is not likely, it must establish a valuation allowance. In the event that actual results differ from these estimates, the Company may need to establish a valuation allowance that could materially impact its financial position and results of operations.

Risks and Uncertainties

The continuation or spread of the current economic uncertainty in key markets would likely harm the Company’s operating results.

     The Company sells products in many geographical regions throughout the world. If economic conditions in any of these regions decline or continue to decline, the demand for the Company’s products is likely to be reduced. Despite economic uncertainty in Europe, the Company showed continued growth in the European market; however, a continuation of an economic downturn in any of its major markets would likely harm its results of operations.

Foreign currency fluctuations and other risks related to international operations may adversely affect the Company’s operating results.

     The Company derived approximately 69% of its net sales from outside North America in the nine months ended March 31, 2005 and expects to continue to derive the majority of net sales from outside North America for the foreseeable future. Most of the Company’s sales outside North America are denominated in the local currency of its customers. As a result, the U.S. dollar value of the Company’s net sales varies with currency rate fluctuations. Significant changes in the value of the U.S. dollar relative to certain foreign currencies could have a material adverse effect on the Company’s results of operations. Tariffs and other trade barriers, difficulties in staffing and managing foreign operations, changes in political environments, interruptions in overseas shipments and changes in tax laws may also impact international sales negatively.

Fluctuation in worldwide demand for analytical instrumentation could affect the Company’s operating results.

19.


Table of Contents

     The demand for analytical instrumentation products can fluctuate depending upon capital expenditure and/or R&D expenditure cycles. Most companies consider the Company’s instrumentation products to be capital equipment and customers may be unable to secure the necessary capital expenditure approvals due to general economic or customer specific conditions. Significant fluctuations in demand could harm the Company’s results of operations.

Fluctuations in the Company’s quarterly operating results may cause the Company’s stock price to decline.

     A high proportion of the Company’s costs are fixed due in part to its significant sales, research and product development and manufacturing costs. Small declines in revenue caused by fluctuations in currency rates, worldwide demand for analytical instrumentation or other factors could disproportionately affect the Company’s quarterly operating results, which may in turn cause its stock price to decline.

If the Company does not introduce new products that are attractive to its customers on a timely basis, the Company’s products may become obsolete.

     The Company’s products are highly technical in nature. As a result, many of the Company’s products must be developed months or even years in advance of the potential need by a customer. If the Company fails to introduce new products and enhancements as demand arises or in advance of the competition, the Company’s products are likely to become obsolete over time, which would harm operating results. Also, if the market is not receptive to newly developed products, the Company may be unable to recover costs of research and product development and marketing, and may fail to achieve material components of its business plan.

The Company’s revenues depend on successfully competing for market share in a highly competitive market.

     The analytical instrumentation market is highly competitive and the Company competes with many competitors on a local and international level that are significantly larger than the Company and have greater resources, including larger sales forces and technical staff.

     Competitors may introduce more effective and less costly products and, in doing so, may make it difficult to acquire and retain customers. If this occurs, the Company’s market share may decline and operating results could suffer.

The Company’s ability to maintain inventories and meet customer demand for its products is critical to its operating results.

     Most raw materials, components and supplies purchased by the Company are available from a number of suppliers. However, certain items are purchased from limited or sole source suppliers and a disruption of these sources could adversely affect the Company’s ability to ship products as needed. A prolonged inability to obtain certain materials or components would likely reduce product inventory, hinder sales and harm the Company’s reputation with customers.

     The Company manufactures products at three sites in Germany, the Netherlands and the United States. Any prolonged disruption to the operations at these facilities, whether due to labor unrest, supplier issues, damage to the physical plants or equipments or other reasons, could also adversely affect the Company’s results of operations.

The Company’s executive officers and other key employees are critical to its business, they may not remain with the Company in the future and finding talented replacements would be difficult.

     The operations of the Company require managerial and technical expertise. Each of the executive officers and key employees located in the United States is employed “at will” and may leave the employment of the Company at any time. In addition, the Company’s headquarters are located in Sunnyvale, California, where the demand for qualified personnel is high and is likely to remain so for the foreseeable future. As a result, competition for personnel is intense and the turnover rate for qualified personnel is comparatively high. The loss of any of the Company’s executive officers or key employees could cause the Company to incur increased operating expenses and divert senior management resources in searching for replacements. An inability to hire, train and retain sufficient numbers of qualified employees would seriously affect the Company’s ability to conduct its business.

The success of the Company’s business is dependent in part on protection of proprietary information and inventions. Obtaining and protecting the Company’s proprietary products, processes and technologies can be difficult and expensive.

     Patent and trade secret protection is important to the Company because developing new technologies and products is time-consuming and expensive. The Company owns many U.S. and foreign patents and intends to apply for additional patents to cover its

20.


Table of Contents

technology and products. The Company may be unable to obtain issued patents from any pending or future patent applications that it owns. The claims allowed under any issued patents may not be sufficiently broad to protect its technology. Third parties may seek to challenge, circumvent or invalidate issued patents that the Company owns.

     In addition to its patents, the Company has a vast number of unpatented proprietary products and know-how. The measures employed by the Company to protect this technology, such as maintaining the confidentiality of proprietary information and relying on trade secret laws, may be inadequate.

     The Company may incur significant expense in any legal proceedings to protect its proprietary rights.

The Company’s failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on its stock price.

     The Company is in the process of documenting and testing its internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which requires annual management assessments of the effectiveness of the Company’s internal control over financial reporting and a report by the Company’s independent registered public accountants attesting to and reporting on these assessments. During the course of the Company’s testing, the Company may identify deficiencies that cannot be remediated in time to meet the deadline imposed by the Sarbanes-Oxley Act for compliance with the requirements of Section 404. In addition, if the Company fails to maintain the adequacy of its internal control over financial reporting, as such standards are modified, supplemented or amended from time to time, it may not be able to ensure that it can conclude in future periods that its has effective internal control over financial reporting in accordance with Section 404. If the Company cannot favorably assess, or its independent registered accountants are unable to provide an unqualified attestation report on the Company’s assessment of, the effectiveness of its internal control over financial reporting, investor confidence in the reliability of the Company’s financial reports may be adversely affected, which could have a material adverse effect on the Company’s stock price.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

     The Company is exposed to financial market risks, including changes in foreign currency rates, interest rates and marketable equity securities, as well as debt and interest expense.

Foreign Currency Exchange.

     Revenues generated from international operations are generally denominated in foreign currencies. The Company enters into forward foreign exchange contracts to hedge against fluctuations of intercompany account balances. Market value gains and losses on these hedge contracts are substantially offset by fluctuations in the underlying balances being hedged, and the net financial impact is not expected to be material in future periods. At March 31, 2005, the Company had forward exchange contracts to sell foreign currencies totaling $19.1 million dollars, including approximately $9.6 million in Euros, $8.4 million in Japanese yen and $1.1 million in Canadian dollars. The foreign exchange contracts at the end of each fiscal quarter mature within the following quarter. Additionally, contract values and fair market values are the same. A sensitivity analysis assuming a hypothetical 10% movement in foreign currency exchange rates applied to hedging contracts and underlying balances being hedged at March 31, 2005 indicated that these market movements would not have a material effect on the Company’s business, operating results or financial condition.

     Foreign currency rate fluctuations can impact the U.S. dollar translation of the Company’s foreign operations in the Company’s condensed consolidated financial statements. Currency fluctuations increased reported net sales by 2% for both the quarter and 4% for the nine months ended March 31, 2005 compared to 11% for the quarter and 8% for the nine months ended March 31, 2005.

Interest and Investment Income.

     The Company’s interest and investment income is subject to changes in the general level of interest rates. Changes in interest rates affect the interest earned on our cash equivalents and short-term investments. A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to the Company’s investment balances at March 31, 2005, indicated that such market movement would not have a material effect on the business, operating results or financial condition. Actual gains or losses in the future may differ materially from this analysis, depending upon actual balances and changes in the timing and amount of interest rate movements.

21.


Table of Contents

Marketable Equity Securities.

     The Company is exposed to market price risks on its marketable equity securities. These investments are in publicly traded companies in the laboratory analytical instruments sector. The Company does not attempt to reduce or eliminate our market exposure on these securities. A 50% adverse change in the equity price would result in an approximate $458,000 decrease in the fair value of its marketable equity securities as of March 31, 2005.

Debt and Interest Expense.

     A sensitivity analysis assuming a hypothetical 10% movement in interest rates applied to the Company’s outstanding debt balance at March 31, 2005, indicated that such market movement would not have a material effect on its business, operating results or financial condition. Actual gains or losses in the future may differ materially from this analysis, depending on the level of the Company’s outstanding debt and changes in the timing and amount of interest rate movements.

ITEM 4. CONTROLS AND PROCEDURES

     The Company carried out an evaluation, under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company’s “disclosure controls and procedures” (as defined in rules promulgated under the Exchange Act). Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures as of March 31, 2005 were effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

     Like many public companies, the Company has been engaged in a diligent review of its disclosure controls and procedures and internal control over financial reporting in order to be able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder when such requirements become applicable to the Company. In connection with these efforts, the Company has identified a number of internal control deficiencies, primarily in the areas of documentation, segregation of duties and information technology systems. The Company’s management does not believe that any of these deficiencies is significant when considered by itself, but believes that such deficiencies could be viewed as significant when taken in the aggregate. An internal control deficiency is “significant” when it results in a more than remote likelihood that a misstatement in the Company’s annual or interim financial statements is more than inconsequential. To address these deficiencies, management is executing a number of initiatives, including modifying existing and launching new management information systems, documenting operating procedures and controls in all of its organizations and improving segregation of duties within its financial organization.

     Other than the initiatives described above, there were no changes in the Company’s internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

     The Company’s management, including the Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s disclosure controls and procedures or its internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with its policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

PART II. OTHER INFORMATION

22.


Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

     Dionex repurchases shares of its common stock under a systematic program to manage the dilution created by shares issued under employee stock plans and for other purposes. This program authorizes repurchases in the open market or in private transactions. The Company started a series of repurchase programs in 1989 with the Board of Directors authorizing future repurchases of an aggregate of 1.5 million shares of common stock in April 2002 as well as authorizing the repurchase of additional shares of common stock equal to the number of common shares issued pursuant to the Company’s employee stock plans.

     The following table indicates common shares repurchased and additional shares added to the repurchase program during the three months ended March 31, 2005:

ISSUER PURCHASES OF EQUITY SECURITIES

                                         
                    Total             Maximum  
                    Shares             Number of  
                    Purchased     Additional     Shares that  
    Total             as Part of     Shares     May Yet Be  
    Number     Avg.     Publicly     Authorized     Purchased  
    of Shares     Price Paid     Announced     for     Under the  
Period   Purchased     per Share     Program(1)     Purchase (1)     Program (1)  
January 1 - 31, 2005
    23,000     $ 58.45       2,688,000       27,426       1,659,699  
 
                                       
February 1 - 28, 2005
    199,700     $ 58.20       2,887,700       148,366       1,608,365  
 
                                       
March 1 - 31, 2005
    23,600     $ 57.81       2,911,300       3,560       1,588,325  


(1)   The current repurchase of 1.5 million shares of common stock plus that number of shares of common stock equal to the number of shares issued pursuant to employee stock plans subsequent to that date.

23.


Table of Contents

Item 6. EXHIBITS

             
Exhibit        
Number   Description   Reference
3.1
  Restated Certificate of Incorporation, filed November 6, 1996     (2 )
 
           
3.2
  Bylaws, as amended on July 29, 2002     (5 )
 
           
4.1
  Shareholder Rights Agreement dated January 21, 1999, between the Registrant and BankBoston N.A.     (3 )
 
           
10.1
  Agreement, effective as of January 1, 1975, between The Dow Chemical Company and International Plasma Corporation     (1 )
 
           
10.2
  Agreement, dated March 6, 1975, between International Plasma Corporation and the former Dionex Corporation     (1 )
 
           
10.3
 
Memorandum agreement, dated March 14, 1975, between The Dow Chemical Company and International Plasma Corporation
    (1 )
 
           
10.4
 
Consent to Assignment executed as of March 26, 1980, between the Dow Chemical Company and the former Dionex Corporation
    (1 )
 
           
10.5
 
Amendatory Agreement, effective as of November 1, 1981,between The Dow Chemical Company and the Registrant (with certain confidential information deleted)
    (1 )
 
           
10.6
 
Amendatory Agreement, effective as of July 1, 1982, between The Dow Chemical Company and the Registrant (with certain confidential information deleted)
    (1 )
 
           
10.7
  Registrant’s Medical Care Reimbursement Plan (Exhibit 10.17)     (1 )
 
           
10.8
  Credit Agreement dated November 13, 2000 between Wells Fargo Bank and the Registrant (Exhibit 10.15)     (4 )
 
           
10.9
  First amendment to Credit Agreement dated November 13, 2000 between Wells Fargo Bank and the Registrant     (6 )
 
           
10.10
  Registrant’s Employee Stock Participation Plan (Exhibit 10.13)     (7 )
 
           
10.10
  Registrant’s Stock Option Plan (Exhibit 99.1)     (8 )
 
           
10.11
  Registrant’s Form of Stock Option Agreement for non-employee directors (Exhibit 99.2)     (8 )

24.


Table of Contents

             
Exhibit        
Number   Description   Reference
10.12
  Registrant’s Form of Stock Option Agreement for other than non-employee directors (Exhibit 99.3)     (8 )
 
           
10.14
 
Second amendment to Credit Agreement dated November 13, 2000 between Wells Fargo Bank and the Registrant (Exhibit 10.1)
    (9 )
 
           
10.15
  Registrant’s Change in Control Severance Benefit Plan.     *  
 
           
21.1
  Subsidiaries of Registrant     (7 )
 
           
31.1
  Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002     *  
 
           
31.2
  Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002     *  
 
           
32.1
  Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002     *  
 
           
32.2
  Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002     *  

*   Filed herewith
 
(1)   Incorporated by reference to the indicated exhibit in Amendment No. 1 of the Registrant’s Registration Statement on Form S-1 filed December 7, 1982.
 
(2)   Incorporated by reference to the corresponding exhibit in the Registrant’s Annual Report on Form 10-Q filed February 13, 1997.
 
(3)   Incorporated by reference to the corresponding exhibit in the Registrant’s Quarterly Report on Form 10-Q filed February 16, 1999.
 
(4)   Incorporated by reference to the indicated exhibit in the Registrant’s Quarterly Report on Form 10-Q filed February 14, 2001.
 
(5)   Incorporated by reference to the indicated exhibit in the Registrant’s Annual Report on Form 10-K filed August 28, 2002.
 
(6)   Incorporated by reference to the indicated exhibit in the Registrant’s Annual Report on Form 10-K filed September 24, 2003.
 
(7)   Incorporated by reference to the indicated exhibit in the Registrant’s Annual Report on Form 10-K filed September 10, 2004.
 
(8)   Incorporated by reference to the Registrant’s Registration Statement on Form S-8 filed December 8, 2004.
 
(9)   Incorporated by reference to the indicated exhibit in the Registrant’s current Report on Form 8-K filed December 22, 2004.

25.


Table of Contents

SIGNATURES

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.

         
 
  DIONEX CORPORATION
(Registrant)
 
       
Date: May 9, 2005
  By:   /s/ Lukas Braunschweiler
       
      Lukas Braunschweiler
      President, Chief Executive Officer And Director
 
       
  By:   /s/ Craig A. McCollam
       
      Craig A. McCollam
      Vice President, and Chief Financial Officer

26.


Table of Contents

Exhibit Index

10.15 Registrant’s Change in Control Severance Benefit Plan.

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2 Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

27.